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Salvage angiogenesis induced by
adenovirus-mediated gene transfer of
vascular endothelial growth factor protects
against ischemic vascular occlusion
Charles A. Mack, MD, Christopher J. Magovern, MD, Kurt T. Budenbender,
BS, Shailen R. Patel, MD, Eric A. Schwarz, MD, Pat Zanzonico, PhD,
Barbara Ferris, BS, Timothy Sanborn, MD, O. Wayne Isom, MD, Ronald G.
Crystal, MD, and Todd K. Rosengart, MD, New York, N.Y.
Purpose: Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogen-
esis, and transgene expression from adenovirus vectors can provide in vivo delivery of
proteins. On the basis of this knowledge, we hypothesized that local administration of
a replication-deficient adenovirus vector expressing complementary DNA for VEGF
(AdVEGF) would induce collateral vessel formation in the setting of ischemia that could
protect against subsequent acute vascular occlusion.
Methods: Hindlimb ischemia was induced in Sprague-Dawley rats by means of unilateral
ligation of the common iliac artery immediately followed by administration of 4 · 109-
plaque-forming units VEGF, the control vector AdNull, or phosphate-buffered saline
solution into the iliofemoral adipose tissue and thigh muscles. Untreated rats with com-
mon iliac ligation were used as an additional control group. 
Results: Local VEGF expression was observed for 5 days in AdVEGF-treated rats but not
in controls. Three weeks after ligation and vector administration, the ipsilateral femoral
artery was ligated for a model of an acute vascular occlusion in the setting of preexist-
ing ischemia. Blood flow to the ischemic hindlimb relative to the contralateral hindlimb
evaluated with color microspheres demonstrated significantly increased blood flow in
the AdVEGF-treated rats compared with each control group (p < 0.0001). Relative
blood flow assessed by means of 99mTc-sestamibi radionuclide scans also demonstrated
increased blood flow to the ligated hindlimb of AdVEGF-treated rats compared with
each control group (p < 0.002). AdVEGF-treated rats also demonstrated increased vas-
cularity in the ligated limb compared with each control group as assessed by means of
angiography (p < 0.0001) and histologic quantification of blood vessels less than 80 m m
diameter in local adipose tissue and capillaries per muscle fiber (p < 0.0002). AdVEGF
treatment prevented a rise in femoral venous lactate femoral venous concentrations 1
hour after femoral artery ligation in control rats (p < 0.04). 
Conclusions: An adenovirus vector expressing VEGF complementary DNA is capable of
stimulating an angiogenic response that protects against acute vascular occlusion in the
setting of preexisting ischemia, suggesting that in vivo gene transfer of VEGF comple-
mentary DNA might be useful in prophylaxis of advancing arterial occlusive disease. 
(J Vasc Surg 1998;27:699-709.)
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Angiogenesis, the growth of new blood vessels,
is a complex process that involves disruption of vas-
cular basement membranes, migration and prolifera-
tion of endothelial cells, and blood vessel formation
and maturation.1 Several mediators are known to
elicit angiogenic responses in vivo, and administra-
tion of these mediators promotes revascularization
of ischemic tissues in experimental models of
myocardial and peripheral vascular ischemia.1-9
Vascular endothelial growth factor (VEGF), a
homodimeric 34 to 46 kd heparin-binding glyco-
protein, is one of the most specific of the known
angiogenic mediators because its receptors are local-
ized almost exclusively on endothelial cells.4,8,10
Consistent with the hypothesis that VEGF plays an
important role in the biologic process of angiogene-
sis, VEGF and the VEGF receptors (flk-1/KDR and
flt-1) are upregulated under ischemic conditions.
Local and systemic administration of recombinant
VEGF protein augments the development of collat-
eral vessels and improves function in experimental
models of peripheral and myocardial ischemia.2,3,5-15
Although VEGF is clearly capable of inducing
angiogenesis, delivery of VEGF for therapeutic pur-
poses presents a challenge. In this regard, the half-
life of VEGF is very short, administration of high
doses of VEGF is associated with hypotension, and
systemic administration of VEGF carries theoretic
risk for promiscuous induction of angiogenesis in
tissues other than the target organ.1,8,9,16 One strat-
egy to circumvent these hurdles is to use a VEGF
complementary deoxyribonucleic acid (cDNA) cod-
ing sequence as the source of local VEGF at the site
of administration.17-21 In this study we evaluated the
hypothesis that a replication-deficient adenovirus
vector that codes for the human VEGF165 cDNA
(AdVEGF) would provide in vivo expression of
VEGF sufficient to induce angiogenesis and enhance
collateralization in the setting of preexisting
ischemia and thereby save threatened tissues from
vascular occlusion. The data show that this strategy
is effective in inducing “salvage angiogenesis” to
preserve blood flow to tissues threatened by acute
vascular occlusion.
METHODS
Experimental model. A model of acute vascu-
lar occlusion superimposed on preexisting ischemia
was created with male Sprague-Dawley rats (250 to
300 gm) (Fig. 1). All procedures and care of rats
were in accordance with institutional guidelines.
Rats were anesthetized with intramuscular ketamine
(100 mg/kg) and xylazine (2 mg/kg). Midline
laparotomy was performed under sterile conditions,
and the left common iliac artery was ligated and
divided. The adenovirus vectors were administered
in the left iliofemoral adipose tissue and muscle. The
abdomen was closed in two layers with nonab-
sorbable suture. AdVEGF (total dose 4 · 109
plaque-forming units), control vector AdNull (total
dose 4 · 109 pfu), or phosphate-buffered saline
solution (PBS; total dose 4 · 100 m l) was adminis-
tered at the time of ligation of the iliac artery in a
volume of 100 m l at each of four sites through a 0.5
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Fig. 1. Schematic of experimental design. Immediately after ligation of the left common iliac
artery, AdVEGF, AdNull, or phosphate-buffered saline solution was administered into the left
hindlimb adipose tissue and muscle (total dose 4 · 109 pfu). An additional control group
underwent left common iliac artery ligation with no injection. Twenty-one days later, the ipsi-
lateral common femoral artery was ligated. The rats were examined for blood flow and vascu-
larity as indicated.
ml syringe with a 30-gauge needle. To achieve a
broad dispersal of vector in the region targeted for
collateral vessel formation, four individual vector
administrations were performed at consistent loca-
tions in the left iliofemoral region of each rat,
including retroperitoneal and inguinal adipose tis-
sue, psoas muscle, and quadriceps muscle. An addi-
tional group of control rats underwent unilateral
common iliac ligation alone with no treatment. 
Three weeks after ligation of the left common
iliac artery and vector administration, rats were anes-
thetized as described earlier, and the left common
femoral artery was ligated and divided at the level of
the inguinal ligament. Immediate analyses of relative
hindlimb blood flow and vascularity were then con-
ducted with, in the following order, 99mTc-labeled
sestamibi, color microspheres, angiography, and his-
tologic quantification of number of blood vessels. In
a separate group of experiments, rats underwent lig-
ation of the common iliac artery and administration
of either AdVEGF or AdNull. Three weeks later,
femoral venous lactate levels were determined just
before and 1 hour after acute ligation of the femoral
artery.
Adenovirus vectors. The replication-deficient
vector AdVEGF is an E1a–, partial E1b–, partial E3–
adenovirus vector that contains an expression cassette
in the E1 position that contains the cytomegalovirus
immediate early promoter-enhancer that drives the
cDNA for the 165 residue form of human VEGF
(VEGF165).20 AdNull (similar to AdVEGF but with
no gene in the expression cassette) was used as a con-
trol vector.22 All adenovirus vectors were propagated
in 293 cells, purified with cesium chloride density
purification, dialyzed, and stored at –70° C as previ-
ously described.23 The titer of each viral stock was
determined by means of plaque assay in 293 cells.23
All viral stocks were demonstrated to be free of repli-
cation-competent wild type adenovirus as previously
described.24
AdVEGF-mediated in vivo expression of
VEGF. To confirm that the AdVEGF vector could
mediate transfer and expression of VEGF cDNA to
adipose tissue and skeletal muscle, an enzyme-
linked immunoassay (ELISA) was used to quantify
VEGF levels in tissue recovered from rats 0, 1, 3, 5,
and 7 days after common iliac ligation and vector
administration (109 pfu/site; n = 3 each time
point). Retroperitoneal adipose tissue and quadri-
ceps muscle of rats treated with the vectors were
harvested, rinsed in PBS pH 7.4, and homogenized
with protein lysis buffer (10 mmol/L tris[hydrox-
ymethyl]aminomethane hydrochloride [TRIS HCl]
at pH 8, 0.14 mol/L sodium chloride, 0.025%
sodium trinhrite, 2% triton X-100, and 1 mmol/L
phenylmethylsulfonyl fluoride [2 ml per gram of tis-
sue]). To confirm that the VEGF produced
remained localized, serum was obtained from each
rat at the aforementioned time points. Protein
determinations were performed with the Bradford
method,25 and ELISA for VEGF (Quantikine
human VEGF immunoassay; R&D Systems,
Minneapolis, Minn.) was performed with 50 m g tis-
sue protein (each assay was performed in duplicate
for each rat). Absorbance was measured at 450 nm
with a microplate reader, and VEGF concentration
was normalized to milligrams protein.
99mTc-labeled sestamibi analysis of hindlimb
blood flow. 99mTc-labeled sestamibi scanning was
used as a measure of blood flow to the hind-
limb.26,27 To accomplish this, the right jugular vein
was identified through a limited right cervical inci-
sion, and 2 to 3 mCi of 99mTc-labeled sestamibi
(Cardiolite; Dupont Pharma, North Billerica, Md.)
in a volume of 0.5 ml of PBS (0.9%) was injected
intravenously. Approximately 15 min after injection,
rats were placed in the supine position on the lower
detector of a Vertex dual head gamma camera sys-
tem (ADAC Laboratories, Milpitas, Calif.), and ven-
tral and dorsal whole-body gamma camera images
were acquired with low-energy high-resolution par-
allel-hole collimators and a photopeak energy win-
dow of 140 keV ± 10%. At least 2 · 105 counts per
rat were acquired simultaneously from the dorsal
(lower detector) and ventral (upper detector)
images. Pegasys computer and image processing
software (ADAC Laboratories) was used to manual-
ly draw consistent rectangular regions of interest
over the center of the calves of the left and right
hindlimbs by an investigator (P.Z.) blinded to the
treatment groups, and the mean counts per pixel in
these regions were determined. Relative blood flow
was reported as the ratio of the region of interest
mean counts per pixel in the ligated (left) hindlimb
to the region of interest mean counts per pixel in the
contralateral (right) control hindlimb for the geo-
metric mean of ventral and dorsal images.
Color microsphere analysis of hindlimb blood
flow. Blood flow to the ischemic (left) hindlimb
relative to the normal (right) hindlimb was evaluat-
ed by means of intraarterial administration of 15 m m
color microspheres as an assessment of functional
blood vessels to the limb.28 The abdominal aorta
was identified through a midline laparotomy and
loosely encircled with a 4-0 silk suture. Immediately
distal to the suture, a 24-gauge, three-quarter inch
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Angiocath catheter (Becton Dickinson Vascular
Access, Sandy, Utah) was inserted into the infrarenal
aorta, and 0.5 ml of a solution of 500 m g/ml nitro-
glycerin (Abbott Laboratories, North Chicago, Ill.)
and 2 · 106 of 15 m m color microspheres (2 · 106
microspheres in 200 m l; E-Z Trac, Los Angeles,
Calif.) was vortexed and injected through the
catheter over 20 seconds to ensure adequate mixing
of the microspheres. 
When the rats were killed, all lower hindlimb calf
muscles were dissected free from skin and bone,
weighed, digested with tissue digest reagents 1 and
2 (E-Z Trac) according to the manufacturer’s
instructions, and resuspended in 50 m l microsphere
counting reagent (E-Z Trac). Microspheres were
counted by an investigator (KB, CAM, SP) blinded
to treatment groups using a manual hemocytometer
with a minimum of 400 spheres counted per sample.
Total number of microspheres and number of
microspheres per gram of tissue were determined,
and relative blood flow was reported for the ligated
hindlimb versus the contralateral control hindlimb.
Hindlimb angiography. Angiography was used
as an assessment of macroscopic vascularity. Rats
were positioned supine 20 cm from the collimator of
a mobile surgical x-ray system (BV25; Philips,
Einhoven, Holland). With a 24-gauge, three-quarter
inch angiocatheter (Becton Dickinson) placed into
the infrarenal aorta, 0.5 ml nitroglycerin (500
m g/ml; Abbott Laboratories) was injected over 20
seconds. Immediately thereafter 3 ml of a prepara-
tion of diatrizoate sodium and diatrizoate meglu-
mine (Renografin-76; Squibb Diagnostics, New
Brunswick, N.J.) was injected through the catheter
into the distal aorta. Fluoroscopic images were
obtained at 2-second intervals. Representative
images demonstrating maximal arterial opacification
were developed, and vascularity was scored by three
blinded observers (CAM, KB, SP). A vascular score
was determined for each rat by means of drawing a
line perpendicular to the midpoint of the long axis
of the femur. The number of vessels that crossed this
line were counted by each observer, averaged, and
reported as the vascular score.
Histologic evaluation of vascularity. Histologic
evaluation was used to quantify vascularity at the
small-vessel level at the sites receiving the adenovirus
vectors. For the treated adipose tissue sites, 1 cm3 adi-
pose tissue samples from sites of vector administration
were retrieved from consistently anatomically equiva-
lent areas, rinsed in PBS and stored in 4% formalin at
4° C. Samples were embedded in paraffin. Five-
micrometer step sections in a plane parallel to the sur-
face of the tissue were obtained at intervals of 50 m m,
and immunohistochemical staining for a -actin was
performed.17 Paraffin sections were blocked with
1.5% horse serum for 20 minutes to prevent nonspe-
cific binding and then exposed to primary antibody
(monoclonal anti-human a -actin; Sigma, St. Louis,
Mo.) at a dilution of 1/500 for 60 minutes. The
slides were exposed sequentially (30 minutes each) to
biotinylated horse anti-mouse immunoglobulin G,
ABC reagents (Vector Laboratories, Burlingame,
Colo.) and new fuchsin substrate for alkaline phos-
phatase (Dako, Carpenteria, Calif.) and were counter-
stained with hematoxylin. Sections were examined by
three blinded observers (CAM, KB, SP) at a magnifi-
cation of 100· . Five random fields of vessels less than
80 m m in diameter were counted per slide; six slides
were evaluated per sample. The counts were averaged
and reported as number of blood vessels per square
millimeter.
To quantify vascularity in treated regions of
skeletal muscle, 1 cm3 sections of quadriceps muscle
from sites of vector administration were retrieved,
rinsed in PBS, and fixed in increasing concentrations
of a sucrose phosphate solution (25° C, 1 hour).
The skeletal muscle specimens were then frozen in a
2:1 20% sucrose/OCT compound mixture (Tissue
Tek; Sakura Finetek, Torrance, Calif.) at –70° C.
The frozen specimens were then cut into 5 m m sec-
tions and frozen on the slides at –70° C. The frozen
slides were warmed to room temperature, stained
for alkaline phosphatase (25° C, 1 hour) with insol-
uble alkaline phosphatase substrate-5-bromo-4-
chloro-3-indolyl phosphate, nitro blue tetrazolium
(BCIP/NBT tablets; Sigma), and counterstained
with eosin. Sections were examined at a magnifica-
tion of 400· by three blinded observers (CAM, KB,
SP). Capillaries per muscle fiber were quantified by
means of counting six random muscle fibers per
field, five random fields per slide, and five slides per
rat. The counts were averaged and reported as num-
ber of capillaries per muscle fiber.29
Assessment of local serum lactate. To assess the
physiologic significance of AdVEGF-mediated in-
crease in relative blood flow, two separate groups of
rats underwent common iliac artery ligation and
administration of either AdVEGF (4 · 109 pfu, n = 5)
or AdNull (4 · 109 pfu, n = 4). Twenty-one days after
common iliac artery ligation and vector administra-
tion (immediately before acute ipsilateral femoral
artery ligation), 400 m l of blood was taken from the
femoral vein of the ligated hindlimb and immediately
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assessed for serum lactate with an electrolyte analyzer
(Nova Biomedical, Waltham, Mass.). One hour after
acute ipsilateral femoral artery ligation, a second 400
m l sample of blood was obtained from the ipsilateral
femoral vein, and serum lactate levels were assessed.
Statistical analysis. Results are presented as
mean ± SEM. Multiple comparisons were carried
out by means of analysis of variance with Bonferroni
adjustment. All other analyses were performed 
with paired and unpaired Student t tests, as appro-
priate. A p value <0.05 was considered statistically 
significant.
RESULTS
AdVEGF-mediated in vivo gene transfer.
Successful AdVEGF-mediated gene transfer and
expression in adipose and skeletal muscle was con-
firmed by means of ELISA (Fig. 2). Endogenous
VEGF could not be detected in serum or in the tis-
sues because the ELISA used for these experiments
allows detection of human VEGF (VEGF165) only
and not rat VEGF. There was no detectable
VEGF165 in either tissue on day 0 (obtained imme-
diately after vector administration), similar to naive
adipose tissue and skeletal muscle. This confirmed
that the vector preparation was not contaminated
with VEGF protein. For both tissues, quantification
of VEGF165 expression demonstrated that adminis-
tration of AdVEGF resulted in VEGF expression,
peaking 1 day after vector administration and
decreasing over several days to baseline by 1 week
after vector administration. In contrast, administra-
tion of the control vector AdNull resulted in no
detectable VEGF165 expression in either tissue at
any time point. Consistent with the concept that
adenovirus vector delivery provides a localized gene
transfer and expression strategy, VEGF was not
detected in the serum of AdVEGF-treated rats at any
of the time points after vector delivery, despite a
lower limit of sensitivity of this assay of 9 pg/ml.
Administration of AdNull did not result in increased
serum levels of VEGF over baseline (not shown).
AdVEGF-mediated increase in relative blood
flow. 99mTc-labeled sestamibi imaging demonstrat-
ed greater relative blood flow to the ischemic
hindlimb in rats treated with AdVEGF compared
with the control groups (p < 0.002) (Figs. 3 and 4).
The scanned radioactive images of AdNull-treated,
PBS-treated, and naive control rats all demonstrated
similarly low levels of radioactivity in the calf region
of the ligated hindlimb (all comparisons p > 0.1).
Color microsphere analysis demonstrated that
relative blood flow after femoral artery ligation in
AdVEGF-treated rats was nearly threefold greater
than that observed for any of the control rats (p <
0.0001; Fig. 5, A). There was no significant differ-
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Fig. 2. Quantification of VEGF expression in injected tissues at various time points by means
of enzyme-linked immunoassay. Immediately after common iliac artery ligation, rats (n = 3 per
time point) received 109 pfu of AdVEGF (closed circles) or the control vector AdNull (open cir-
cles). A. Adipose tissue. B. Muscle. Vector administration was at time zero; the first time point
represents naive tissue before treatment.
ence in the relative blood flow among the three con-
trol groups (p > 0.3; Fig. 5, A). In addition, the total
number of microspheres counted in the ligated
hindlimb muscles were significantly greater in the
AdVEGF-treated rats compared with each control
group (p < 0.0001; Fig. 5, B). The total number of
microspheres counted in the contralateral lower
hindlimb muscles of AdVEGF-treated rats was
approximately the same as that for control rats 
(Fig. 5, B). Therefore the increase in relative blood
flow among AdVEGF-treated rats compared with
controls, calculated as the ratio of microspheres per
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Fig. 3. Representative 99mTc-labeled sestamibi images at 21 days for the four experimental
groups of rats. A, Naive. B, Phosphate-buffered saline solution. C, Control vector AdNull.
D-F, AdVEGF. Shown for each are the color images acquired from the dorsal and ventral
detectors of the lower trunk, right (R) and left (L) hindlimbs, and the tail. The central abdom-
inal regions are deleted. Yellow, highest flow. Orange, purple, and blue represent decreasing rel-
ative flow. Arrows indicate the ligated left hindlimb. There is reconstitution of flow in the left
hindlimb only in the AdVEGF-treated rat.
gram tissue in the ligated hindlimb versus micro-
spheres per gram tissue in the contralateral control
hindlimb, resulted from an increase in the number
of microspheres in the ligated hindlimb, not a
decrease in the number of spheres in the contralat-
eral control hindlimb.
To confirm that there was adequate mixing of
color microspheres during injection, relative blood
flow was quantified for a separate group of rats with-
out iliac or femoral ligation (n = 6). Relative blood
flow (left versus right) among these rats was 99 ± 7%
(not shown; left versus right p > 0.8).
AdVEGF-mediated increased vascularity.
Angiography demonstrated significantly greater vas-
cularity in the ligated hindlimbs of AdVEGF-treated
rats than those of controls (Fig. 6). The angiograph-
ic vessel score in the ligated hindlimbs of AdVEGF-
treated rats was significantly greater than that of
naive, PBS-treated, and AdNull-treated controls (p <
0.0001). The numbers of angiographically visible
collateral vessels in AdNull-treated, PBS-treated, and
naive control rats were similar (p > 0.09).
Results of histologic evaluation of vascularity 
in adipose tissue and skeletal muscle were consistent
with the observations of relative blood flow and
angiographic evidence of enhanced vascularity.
Compared with the naive, PBS-treated, and AdNull-
treated controls, a significantly greater number of
small blood vessels (less than 80 m m diameter) were
observed 21 days after vector administration in the
AdVEGF-injected adipose tissue (p < 0.0001; Fig. 7,
A). Histologic evaluation of AdVEGF-treated quadri-
ceps skeletal muscle also demonstrated a significantly
greater number of capillaries per muscle fiber 21 days
after vector administration compared with the naive,
PBS-treated, and AdNull-treated controls (p <
0.0002; Fig. 7, B).
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Fig. 4. Relative blood flow assessed by means of 99mTc-
labeled sestamibi imaging in hindlimbs immediately after
ligation of left femoral artery. The experimental model is as
described in Fig. 1. Relative blood flow is quantified as the
ratio of left versus right geometric mean counts per pixel of
dorsal and ventral views of the calf of the ligated hindlimb
(left) to the same area of the contralateral hindlimb (right).
Each experimental condition included a minimum of seven
rats (AdVEGF versus controls p < 0.05).
Fig. 5. Relative blood flow assessed with color micro-
spheres in hindlimbs. The experimental model is as
described in Fig. 1. After ligation of the femoral artery,
color microspheres were injected into the infrarenal aorta.
Relative blood flow is expressed as microspheres per gram
tissue in the ligated hindlimb (left) versus microspheres
per gram tissue in the contralateral (right) hindlimb (A)
and as raw number of microspheres observed in the total
lower hindlimb muscles of the ligated hindlimbs (left) and
contralateral hindlimb (right) (B). Each experimental con-
dition included a minimum of eight rats (AdVEGF versus
controls p < 0.004).
Physiologic assessment of AdVEGF-mediated
increase in relative blood flow. To further con-
firm that AdVEGF-mediated collateralization pro-
vided physiologically relevant protection of distal
blood flow and prevention of ischemic compromise,
serum lactate levels were determined from femoral
venous blood samples taken immediately before
(baseline) and 1 hour after acute vascular occlusion
(Table I). Local serum lactate levels were similar in
each group of rats before acute ipsilateral femoral
artery ligation. However, 1 hour after acute ipsilat-
eral femoral artery ligation, femoral venous lactate
levels were significantly higher among the AdNull-
treated rats compared with AdVEGF-treated rats
(AdVEGF compared with AdNull-treated rats
p < 0.04). 
DISCUSSION
This study demonstrated that a single adminis-
tration of adenovirus vector expressing the cDNA of
human VEGF165 to adipose and skeletal muscle tis-
sues surrounding a site of vascular occlusion induces
a physiologically relevant angiogenic response ade-
quate to attenuate the ischemia caused by acute vas-
cular occlusion. These findings suggest that angio-
genic mediators can enhance angiogenic responses
after an acute ischemic event and salvage ischemic
tissues threatened by subsequent acute vascular
occlusion weeks after the expressed angiogenic pro-
tein is no longer detectable. Such observations
potentially expand the horizon for therapeutic
angiogenesis to include the prophylactic treatment
of patients with preexisting ischemia threatened by
an acute vascular occlusive event.
Vascular endothelial growth factor as a medi-
ator of therapeutic angiogenesis. Extensive data
have accumulated implicating the role of VEGF in
normal embryonic development, normal growth
and differentiation, wound healing, and reproduc-
tion and in the pathogenesis of neoplasia, rheuma-
toid arthritis, and proliferative retinopathy.1,4,8,10,30
Upregulation of VEGF and its receptors flk-1/KDR
and flt-1 in association with hypoxic conditions of
cultured cells in vitro and in association with local
hypoxia in vivo suggests the relevance of this growth
factor in inducing angiogenesis in the ischemic set-
ting.1,4,10-15
The use of the VEGF protein to induce thera-
peutic angiogenesis has been demonstrated in a num-
ber of studies. In vitro studies demonstrated VEGF
binding and induction of angiogenesis in rat tis-
sues.2,3,5-7,9,17,19-21,30-32. In rabbit hind limb models
of ischemia, a single intraarterial bolus or repeat
administration of VEGF induced increased vasculari-
ty and blood flow and improved both hemodynamic
and clinical function.3,6,7,33 Angiogenesis and
increased myocardial infusion also have been demon-
strated with daily administration of VEGF through
an in dwelling catheter over 28 days in a canine
model2 and by means of continuous administration
of VEGF to the myocardium over 6 weeks in a
porcine model of myocardial ischemia.5
The choice of VEGF for this study was based on
the efficacy of VEGF in inducing angiogenesis in
previous studies and the endothelial cell specificity of
VEGF. In regard to the latter, other growth factors
stimulate growth of cells such as fibroblasts, smooth
muscle cells, and endothelial cells, and theoretically
use of these factors carries risk for unwanted fibrosis
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Table I. Assessment of local serum lactate
Group Baseline (0 hr) After ligation (1 hr)
AdNull 0.53 ± 0.15 1.40 ± 0.40*
AdVEGF 0.58 ± 0.18 0.50 ± 0.11
Lactate levels are expressed as mean value ± SEM in millimoles
per liter. 
*Significantly elevated from baseline p < 0.04.
Fig. 6. Angiographic evaluation of vascularity in
ischemic hindlimbs after ligation of the left femoral
artery. The experimental model is as described in Fig. 1.
Angiographic quantification of vascularity was performed
by three blinded observers. Each experimental condition
included a minimum of eight rats (AdVEGF versus con-
trols p < 0.001).
or smooth muscle cell hyperplasia.1,34,35 The work
of Lazarous et al.9 provided evidence of intimal
hyperplasia induced by VEGF. This outcome cannot
be discounted in considering the potential for VEGF
to activate other growth factors through indirect
mechanisms and in noting the positive a -actin stain-
ing of mesenchymal cells induced by AdVEGF in
this study. Nevertheless, intimal hyperplasia has not
been characteristic of VEGF therapy in this or other
studies.
Adenovirus-mediated gene transfer as a strat-
egy for vascular endothelial growth factor–relat-
ed therapeutic angiogenesis. Gene therapy can be
viewed simply as a drug delivery system in which the
gene (for example, VEGF cDNA) is the drug. Gene
transfer provides the equivalent of a sustained-
release capsule whereby disbursing high concentra-
tions of the therapeutic protein are dispensed for an
extended period. Although the period of peak
VEGF expression in this study was approximately 3
days, the AdVEGF vector has been demonstrated to
provide detectable expression of the VEGF protein
for up to 7 days.17,18 In contrast, VEGF administra-
tion as a protein is characterized by a very short bio-
logic half-life of the growth factor in the circula-
tion.7,9 Although this does not take into account
local tissue concentrations of VEGF, most previous
studies of angiogenic therapy have required contin-
uous infusions or repetitive dosing of the growth
factors consistent with the concept that it may be
necessary to administer the angiogenic proteins
repetitively to achieve a therapeutic effect.
Gene transfer can be strategized to provide local-
ized regional delivery of a high concentration of
VEGF to the ischemic site. Localization of ade-
novirus-mediated VEGF transgene expression was
not specifically examined in this study. However,
AdVEGF administration resulted in no increase in
vessel number in the contralateral hindlimb com-
pared with normal controls. These findings are con-
sistent with those in our previous studies in which
the pharmacokinetics and localized distribution of
adenovirus-mediated delivery were analyzed in
detail.17,18 In these studies, no angiogenic effect was
detected contralateral to a retroperitoneal injection
of AdVEGF, and no discernable increases in VEGF
concentrations were detectable in other organs or
myocardium beyond immediate proximity to
myocardial AdVEGF injection sites. In contrast, sys-
temic administration of an angiogenic factor can
induce hypotension and carries theoretic risk for
inducing inappropriate angiogenesis at sites of vas-
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Fig. 7. Results of histologic evaluation of vascularity in adipose tissue and skeletal muscle in
ischemic hindlimbs after ligation of the left femoral artery. The experimental model is as
described in Fig. 1. A, Adipose tissue. Histologic quantification of small-vessel (less than 80
m m diameter) count is expressed as mean number of vessels per square millimeter (AdVEGF
versus controls p < 0.0003.). B. Skeletal muscle. Histologic quantification of capillary number
in skeletal muscle is depicted as capillaries per muscle fiber (AdVEGF versus controls p <
0.002). Each experimental condition includes a minimum of seven rats.
cular derangement or sites where angiogenesis
might have adverse consequences, such as the retina,
the synovium, and occult tumors.1,9,16
Three gene transfer systems have been used to in-
duce angiogenesis with VEGF in experimental mod-
els: adenovirus, herpesvirus, and plasmids.17,19,21 We
have focused on adenovirus vectors for several reasons.
Adenovirus vectors achieve gene transfer to both
dividing and nondividing cells with high levels of effi-
ciency and can induce protein expression in relevant
cardiovascular sites, such as skeletal muscle, myo-
cardium, and vascular endothelium.17,18,23,29,37-44
Gene transfer by an adenovirus vector into an
epichromosomal position carries little risk for inap-
propriate insertion of the newly transferred gene at a
critical site in the genome43 and is characterized by
transgene expression for 1 to 2 weeks, long enough
to induce angiogenesis but limited enough to mini-
mize theoretic risk for inappropriate, disorganized
blood vessel formation caused by prolonged expres-
sion.17,18,20,29,37-44 A theoretic disadvantage of ade-
novirus vectors is that neutralizing antibodies direct-
ed against the vector might limit the effectiveness of
repeated vector administration. This hurdle can like-
ly be overcome by use of adenovirus vectors of dif-
ferent serotypes or by immunosuppressive thera-
py.45,46 Previous studies of AdVEGF administration
to retroperitoneal adipose tissue demonstrated persis-
tence of the AdVEGF-generated vasculature for up
to 90 days after vector administration, even though
VEGF transgene expression is undetectable 1 week
after injection.17
Adenovirus-mediated angiogenesis as biologic
revascularization strategy. The primary signifi-
cance of our results is that with a single therapeutic
injection of an adenovirus vector containing VEGF
cDNA, levels of angiogenic growth factor expression
can be achieved in vivo. This expression produces
collateral vessel formation adequate to improve per-
fusion to tissues threatened by acute vascular occlu-
sion. With evidence that adenovirus vectors are capa-
ble of delivering new genetic information safely to
humans in vivo24,43 and that VEGF is capable of
inducing angiogenesis in vivo,2,3,5-7,9,17,19-21 it is rea-
sonable to hypothesize that this gene transfer strate-
gy can be used clinically as an adjunct or alternative
to conventional therapies to promote collateral vessel
development and protect ischemic tissues threatened
by superimposed acute vascular occlusion.
We thank Heather Carpenter, Emily Cogger, Neil
Hackett, and Phil Leopold in our laboratory and Martin
Lesser, PhD, for assistance with statistical analysis.
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